Galinpepimut-S

Phase 2Biologic

SSellas Life Sciences Group

Galinpepimut-S is one of 134 biologic programs targeting Malignant Pleural Mesothelioma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

133

Competitors

Pipeline

Status by Indication[3][1]

Indication

Malignant Pleural MesotheliomaActive, not recruiting

MesotheliomaActive, not recruiting

Acute Lymphoblastic LeukemiaActive, not recruiting

Multiple MyelomaActive, not recruiting

Malignant Pleural MesotheliomaPhase 2

Active, not recruiting

MesotheliomaPhase 1

Active, not recruiting

Acute Lymphoblastic LeukemiaPhase 2

Active, not recruiting

Multiple MyelomaPhase 1/Phase 2

Active, not recruiting

Competition

Competitive Landscape

1135 competitors in Multiple Myeloma

#DrugCompanyPhaseTrials

Ninlaro

Takeda

Preclinical

18 2

Galinpepimut-S

SSellas Life Sciences Group

Phase 2

1 3

Prolia

Amgen

Preclinical

5 4

Eliquis

Bristol-Myers Squibb

Preclinical

3 5

Epogen

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Preclinical

2 6

Adriamycin

GGynecologic Oncology Group

Preclinical

9 7

Nolvadex

AstraZeneca

Preclinical

1 8

Oncovin

EEastern Cooperative Oncology Group

Preclinical

8 9

Intron a

Systemic Therapy

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2026

Phase 3Active, not recruiting

AIN

NCT04229979

Clinical

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

WT1 Vaccine Treatment of Patients in Remission From Acute Myeloid Leukemia (AML) or Acute Lymphoblastic Leukemia (ALL)

Completed·SSellas Life Sciences Group·Phase 2·NCT01266083·22 enrolled

Malignant Pleural Mesothelioma1 trial

Galinpepimut-S (WT-1 Analog Peptide) Vaccine in Malignant Pleural Mesothelioma After Combined Modality Therapy

Completed·SSellas Life Sciences Group·Phase 2·NCT01265433·41 enrolled

Multiple Myeloma1 trial

WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

Completed·SSellas Life Sciences Group·Phase 1/2·NCT01827137·20 enrolled

MDS1 trial

Expanded Access Program (EAP) for Galinpepimut-S (GPS) in Patients Diagnosed With AML or MDS

Available·SSellas Life Sciences Group··NCT05593185

Advanced Cancers1 trial

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

Completed·SSellas Life Sciences Group·Phase 1/2·NCT03761914·26 enrolled

2 more indications

AIN1 trial

Galinpepimut-S Versus Investigator's Choice of Best Available Therapy for Maintenance in AML CR2/CRp2

Active, not recruiting·SSellas Life Sciences Group·Phase 3·NCT04229979·127 enrolled

Mesothelioma1 trial

Using a Targeted Cancer Vaccine (Galinpepimut-S) With Immunotherapy (Nivolumab) in Mesothelioma

Completed·MMemorial Sloan Kettering Cancer Center·Phase 1·NCT04040231·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 7 trial records for Galinpepimut-S. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Galinpepimut-S compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Galinpepimut-S. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sellas Life Sciences Group company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 2[1]
Company: SSellas Life Sciences Group

Galinpepimut-S

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2026

Trials by Indication[1]

Acute Lymphoblastic Leukemia1 trial

Malignant Pleural Mesothelioma1 trial

Multiple Myeloma1 trial

MDS1 trial

Advanced Cancers1 trial

AIN1 trial

Mesothelioma1 trial

References

Drug Info

Quick Facts

Related News